Alejandro Rojo-Sebastián

Alejandro Rojo-Sebastián

Auto-generated profile, based on publicly available information

Alejandro Rojo-Sebastián

University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMarta Hergueta-Redondo
Marta Hergueta-Redondo
DSDavid Sarrió
David Sarrió
ÁMÁngela Molina-Crespo
Ángela Molina-Crespo
DMDiego Megias
Diego Megias
AMAlba Mota
Alba Mota
GMGema Moreno-Bueno
Gema Moreno-Bueno
Gasdermin B (GSDMB) belongs to the Gasdermin protein family that comprises four members (GSDMA-D). Gasdermin B expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-expression has been related to tumor progression. At least four splicing isoforms of GSDMB have been identified, which may play differential roles in cancer. However, the implication of GSDMB in carcinogenesis and tumor progression is not well understood. Here, we uncover for the first time the functional implication of GSDMB in breast cancer. Our data shows that high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients included in an expression dataset (>1,000 cases). We demonstrate that GSDMB is upregulated in breast carcinomas compared to normal breast tissue, being the isoform 2 (GSDMB-2) the most differentially expressed. In order to evaluate the functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2). The overexpression of both isoforms in the MCF7 breast carcinoma cell line promotes cell motility and invasion, while its silencing in HCC1954 breast carcinoma cells decreases the migratory and invasive phenotype. Importantly, we demonstrate that both isoforms have a differential role on the activation of Rac-1 and Cdc-42 Rho-GTPases. Moreover, our data support that GSMDB-2 induces a pro-tumorigenic and pro-metastatic behavior in mouse xenograft models as compared to GSDMB-1. Finally, we observed that although both GSDMB isoforms interact in vitro with the chaperone Hsp90, only the GSDMB-2 isoform relies on this chaperone for its stability. Taken together, our results provide for the first time evidences that GSDMB-2 induces invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic marker in breast cancer.

6 July 2011 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
GMGema Moreno-Bueno
Gema Moreno-Bueno
FSFernando Salvador
Fernando Salvador
AMAlberto Martín
Alberto Martín
AFAlfredo Floristán
Alfredo Floristán
ECEva P Cuevas
Eva P Cuevas
ACAmparo Cano
Amparo Cano
Basal‐like breast carcinoma is characterized by the expression of basal/myoepithelial markers, undifferentiated phenotype, highly aggressive behaviour and frequent triple negative status (ESR−, PR−, Her2neu−). We have previously shown that epithelial–mesenchymal transition (EMT) occurs in basal‐like breast tumours and identified Lysyl‐oxidase‐like 2 (LOXL2) as an EMT player and poor prognosis marker in squamous cell carcinomas. We now show that LOXL2 mRNA is overexpressed in basal‐like human breast carcinomas. Breast carcinoma cell lines with basal‐like phenotype show a specific cytoplasmic/perinuclear LOXL2 expression, and this subcellular distribution is significantly associated with distant metastatic incidence in basal‐like breast carcinomas. LOXL2 silencing in basal‐like carcinoma cells induces a mesenchymal‐epithelial transition (MET) associated with a decrease of tumourigenicity and suppression of metastatic potential. Mechanistic studies indicate that LOXL2 maintains the mesenchymal phenotype of basal‐like carcinoma cells by a novel mechanism involving transcriptional downregulation of Lgl2 and claudin1 and disorganization of cell polarity and tight junction complexes. Therefore, intracellular LOXL2 is a new candidate marker of basal‐like carcinomas and a target to block metastatic dissemination of this aggressive breast tumour subtype.

6 June 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JAJ. Albanell
J. Albanell
AGA. González
A. González
MRM. Ruiz-Borrego
M. Ruiz-Borrego
EAEmilio Alba
Emilio Alba
JGJosé Ángel García-Saénz
José Ángel García-Saénz
ALA. Lluch
A. Lluch
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Enrollment was offered consecutively to eligible women with estrogen receptor-positive; human epidermal growth factor receptor 2-negative, node-negative breast cancer. Oncologists recorded treatment recommendation and confidence in it before and after knowing the patient’s RS. Treatment recommendation changed in 32% of 107 patients enrolled: in 21% from chemohormonal (CHT) to hormonal therapy (HT) and in 11% from HT to CHT. RS was associated with the likelihood of change from HT to CHT (P < 0.001) and from CHT to HT (P < 0.001). Confidence of oncologists in treatment recommendations increased for 60% of cases. Higher tumor grade (P = 0.007) and a high proliferative index (Ki-67) (P = 0.023) were significantly associated with a greater chance of changing from HT to CHT, while positive progesterone receptor status (P = 0.002) with a greater probability of changing from CHT to HT. Results from the first prospective European study are consistent with published experience and use of the RS as proposed in European clinical practice guidelines and provide evidence on how Oncotype DX and clinicopathological factors are complementary and patient selection may be improved.

22 July 2016 in Oncotarget
Verified
Journal Article
Open access
MHMarta Hergueta-Redondo
Marta Hergueta-Redondo
DSDavid Sarrio
David Sarrio
ÁMÁngela Molina-Crespo
Ángela Molina-Crespo
RVRocío Vicario
Rocío Vicario
CBCristina Bernadó-Morales
Cristina Bernadó-Morales
GMGema Moreno-Bueno
Gema Moreno-Bueno
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

1 November 2008 in Gynecologic Oncology
Verified
Journal Article
Closed access
LCLuis Chiva
Luis Chiva
FLFernando Lapuente
Fernando Lapuente
LGLucia González-Cortijo
Lucia González-Cortijo
NCNatalia Carballo
Natalia Carballo
JGJuan F. García
Juan F. García
AGAntonio González-Martín
Antonio González-Martín

20 December 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
PGPablo García‐Sanz
Pablo García‐Sanz
JTJuan Carlos Triviño
Juan Carlos Triviño
AMAlba Mota
Alba Mota
MLMaría Pérez López
María Pérez López
ECEva Colás
Eva Colás
GMGema Moreno-Bueno
Gema Moreno-Bueno
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non‐endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low‐grade, non‐ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE‐positive endometrioid endometrial carcinomas (EECs). We performed exome‐sequencing of 11 EECs with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodelling‐related genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA‐repair‐related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency toward co‐occurrence (RAD50‐KMT2D and RAD50‐SETD1B). All these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches.